Updated Guidance for the Pharmacological Treatment of Clostridium Difficile Infections
This CE will provide pharmacists updated guidelines and best practices for treating Clostridium Dificile Infections (CDI). The updated guidance takes into account data that has emerged to support the use of new treatments in the management of CDI. The latest instructions will introduce pharmacists to up to date protocols for the initial treatment, recurrent episodes, as well as new recommendations for adjunctive treatment in CDI.
Upon completion of this activity, the participant will be able to:
- Use the 2021 IDSA/SHEA guidelines and emerging clinical evidence to improve current practice in the treatment of CDI.
- Explain the place in therapy of bezlotoxumab for the management of CDI.
- Compare characteristics of various pharmacologic treatment options for the management of CDI.
Shane J. Softy, B.S., PharmD., is a current PGY-1 acute-care pharmacy resident at Mount Auburn Hospital as part of the Beth Israel Lahey Health System. He has received a Bachelor of Science degree from Virginia Polytechnic Institute and State University with a major in Animal and Poultry Sciences and a minor in Chemistry and Psychology. He went on to receive his Doctorate-of-Pharmacy from Virginia Commonwealth University.
Residency Mentor: Oussayma Moukhachen, PharmD., BCPS, BCCCP
Registration Fee: This module is provided free of charge to all.
Release Date: March 14, 2022
Expiration Date: March 14, 2023
ACPE UAN: 0026-0000-22-001-H01-P | Knowledge
ACPE Topic Designator: Drug Therapy
Contact Hours: 1.0 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1.0 contact hour (0.1 CEU).
To receive credit, participants must complete pre and post-assessments, view the entire presentation, and evaluate the session. Participant credit will be reported to the CPE Monitor upon conclusion. Transcripts may be printed from the CPE Monitor.
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Shane Softy and Oussayma Moukhachen have no relevant financial relationships with ineligible companies to disclose.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.